The hyperdeliverability of the latest evolution of drug-eluting stents should not cause any steps to be omitted during percutaneous coronary intervention - 19/09/21
L’hyperdélivrabilité de la dernière évolution des stents à élution médicamenteuse ne doit pas faire oublier certaines étapes d’une procédure d’angioplastie
Doi : 10.1016/j.acvd.2021.08.001
Gilles Barone-Rochette a, b, c, 1, ⁎ 
a Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, LRB, 38000 Grenoble, France
b Department of Cardiology, CHU Grenoble Alpes, 38000 Grenoble, France
c French Alliance Clinical Trial, French Clinical Research Infrastructure Network, 75018 Paris, France
⁎Correspondence at: Department of Cardiology, CHU Grenoble, BP 217, 38043 Grenoble CEDEX 09, France.Department of Cardiology, CHU GrenobleBP 217Grenoble CEDEX 0938043France
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Sunday 19 September 2021
This article has been published in an issue click here to access
This article has been published in an issue click here to access
Keywords : Ultrathin-strut drug-eluting stent, Hyperdeliverability, Optimal implantation techniques
Mots clés : Endoprothese coronaire active avec maille ultrafine, Hyper-délivrabilité, Techniques d’implantation optimales
Abbreviations : DES, PCI, ST
Esquema
| ☆ | Tweet: Stent thrombosis is equally a result of stent-, procedure-, lesion- and patient-related factors. Improvements made to drug-eluting stent with hyperdeliverability should not have a deleterious effect on other factors, such as the PCI procedure. |
© 2021
Elsevier Masson SAS. Reservados todos los derechos.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?